Genmab (BST:GE91) - Aandelenkoers, Nieuws & Analyse

GE91 Overzicht aandelen

Genmab A/S ontwikkelt therapeutica op basis van antilichamen voor de behandeling van kanker en andere ziekten, voornamelijk in Denemarken. Meer informatie

GE91 fundamentele analyse
Sneeuwvlok Score
Waardering	5/6
Toekomstige groei	4/6
Prestaties in het verleden	4/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

Verhandeld tegen 84.8% onder onze schatting van de reële waarde

De winst zal naar verwachting met 23.73% per jaar groeien

De winst groeide het afgelopen jaar met 12.9%

Handelen tegen een goede waarde vergeleken met branchegenoten en branchegenoten

Risicoanalyse

Geen risico's gedetecteerd voor GE91 uit onze risicocontroles.

Genmab A/S Concurrenten

Biotest

XTRA:BIO3

€1.4b

Formycon

XTRA:FYB

€818.4m

Sartorius

XTRA:SRT3

€13.4b

SCHOTT Pharma KGaA

XTRA:1SXP

€4.0b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Genmab
Historische aandelenkoersen
Huidige aandelenkoers	DKK 19.60
52 Week Hoogtepunt	DKK 30.20
52 Week Laag	DKK 19.60
Bèta	0.86
11 maand verandering	-9.26%
3 maanden verandering	-17.65%
1 Jaar Verandering	-34.67%
33 jaar verandering	-46.45%
5 jaar verandering	-6.06%
Verandering sinds IPO	20.82%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	GE91	DE Biotechs	DE Markt
7D	-7.5%	-1.0%	-0.5%
1Y	-34.7%	-16.7%	8.3%

Rendement versus industrie: GE91 presteerde slechter dan de German Biotechs -sector, die het afgelopen jaar een rendement van -16.7 % opleverde.

Rendement versus markt: GE91 presteerde slechter dan German Market, dat het afgelopen jaar een rendement van 8.3 % opleverde.

Prijsvolatiliteit

Is GE91's price volatile compared to industry and market?
GE91 volatility
GE91 Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.4%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	11.0%
10% least volatile stocks in DE Market	2.4%

Stabiele aandelenkoers: Er zijn geen gegevens beschikbaar.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van GE91 in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1999	2,635	Jan G.J. de Winkel	www.genmab.com

Genmab A/S ontwikkelt therapeutica op basis van antilichamen voor de behandeling van kanker en andere ziekten, voornamelijk in Denemarken. Het bedrijf brengt DARZALEX op de markt, een humaan monoklonaal antilichaam voor de behandeling van patiënten met multipel myeloom (MM); teprotumumab voor de behandeling van schildklieroogaandoeningen; en amivantamab voor gevorderde of gemetastaseerde maag- of slokdarmkanker en NSCLC. Haar producten omvatten daratumumab voor de behandeling van MM, niet-MM bloedkankers en AL amyloïdose; GEN1047; tisotumab vedotin voor de behandeling van baarmoederhals-, eierstok- en solide kankers; DuoBody-PD-L1x4-1BB, en DuoBody-CD40x4-1BB voor de behandeling van solide tumoren; Epcoritamab voor recidief/refractair diffuus groot B-cel lymfoom en chronische lymfocytaire leukemie; en HexaBody-CD38 en GEN3017 voor de behandeling van hematologische maligniteiten.

Genmab A/S Samenvatting

Hoe verhouden de winst en inkomsten van Genmab zich tot de beurswaarde?
GE91 fundamentele statistieken
Marktkapitalisatie	€12.35b
Inkomsten(TTM)	€630.34m
Inkomsten(TTM)	€2.66b

19.6x

Koers/Winstverhouding

4.6x

P/S-verhouding

Is GE91 overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
GE91 resultatenrekening (TTM)
Inkomsten	DKK 19.84b
Kosten van inkomsten	DKK 774.00m
Brutowinst	DKK 19.07b
Overige uitgaven	DKK 14.37b
Inkomsten	DKK 4.70b

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	74.03
Brutomarge	96.10%
Nettowinstmarge	23.69%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde GE91 op de lange termijn?

Bekijk historische prestaties en vergelijking

GE91 Overzicht aandelen

Beloningen

Risicoanalyse

Genmab A/S Concurrenten

XTRA:BIO3

€1.4b

XTRA:FYB

€818.4m

XTRA:SRT3

€13.4b

XTRA:1SXP

€4.0b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Genmab Announces New Data from the Phase 1/2 Study Of Rinatabart Sesutecan (Rina-S), an Investigational Folate Receptor-Alpha (FRa)-Targeted, Topo1 Antibody-Drug Conjugate

Genmab A/S Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Executive Changes

Genmab A/S Takes Full Control of Acasunlimab Development Program

Genmab A/S Announces That the U.S. Food and Drug Administration Approved Epkinly® (Epcoritamab-Bysp) for the Treatment of Adults with Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic EPKINLY

Genmab A/S Announces New Efficacy and Safety Data from Two Ongoing Phase 1/2 Clinical Trials Evaluating Epcoritamab, A T-Cell Engaging Bispecific Antibody Administered Subcutaneously, in Adult Patients with Certain Types of Follicular Lymphoma

Recent updates

Genmab Announces New Data from the Phase 1/2 Study Of Rinatabart Sesutecan (Rina-S), an Investigational Folate Receptor-Alpha (FRa)-Targeted, Topo1 Antibody-Drug Conjugate

Genmab A/S Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Executive Changes

Genmab A/S Takes Full Control of Acasunlimab Development Program

Genmab A/S Announces That the U.S. Food and Drug Administration Approved Epkinly® (Epcoritamab-Bysp) for the Treatment of Adults with Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic EPKINLY

Genmab A/S Announces New Efficacy and Safety Data from Two Ongoing Phase 1/2 Clinical Trials Evaluating Epcoritamab, A T-Cell Engaging Bispecific Antibody Administered Subcutaneously, in Adult Patients with Certain Types of Follicular Lymphoma

Genmab A/S (CPSE:GMAB) completed the acquisition of ProfoundBio, Inc.

Genmab A/S to Present New and Updated Results from Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies At the 2024 European Hematology Association (Eha) Congress

Pfizer Inc. and Genmab A/S Announce FDA Grants Full Approval for TIVDAK to Treat Recurrent or Metastatic Cervical Cancer

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S Announces Executive Changes

Genmab A/S and AbbVie Announce U.S. Food and Drug Administration Grants Priority Review for the Supplemental Biologics License Application for Epcoritamab (Epkinly®) for Difficult-To-Treat Relapsed or Refractory Follicular Lymphoma

Genmab A/S and Pfizer, Inc. Announces Validation for Review the Marketing Authorization Application of Tivdak®?

Genmab A/S Announces Decision in Arbitration Appeal Under License Agreement with Janssen Biotech, Inc

Pfizer Inc. and Genmab A/S Announce U.S. Food and Drug Administration Accepts TIVDAK® Supplemental Biologics License Application

Genmab A/S and AbbVie Announces New Pivotal Data for Bispecific Antibody Epcoritamab (Duobody CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Genmab A/S Revises Earnings Guidance for the Year 2023

Genmab A/S, Annual General Meeting, Mar 13, 2024

Genmab A/S to Report Q1, 2024 Results on May 02, 2024

Genmab A/S and Seagen Inc. Announce Additional Results from the Phase 3 innovaTV 301 Randomized Global Trial

Genmab A/S Announces European Commission Approval of Tepkinly(R) (epcoritamab) for Adults with Relapsed Or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Seagen Inc. and Genmab A/S Announce That Tivdak(R) (Tisotumab Vedotin-Tftv) Met Its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy

Genmab A/S Revises Earning Guidance for the Year 2023

Genmab A/S Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY(R) Diffuse Large B-Cell Lymphoma

AbbVie and Genmab Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

Genmab A/S Announces Epcoritamab Added to National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for ‘B-Cell Lymphomas’

Genmab A/S Showcases Data from Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas At European Hematology Association (EHA) Annual Meeting 2023

U.S. Food and Drug Administration Approves Genmab A/S’s EPKINLY (epcoritamab-bysp) as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory Diffuse Large B-cell Lymphoma

Genmab A/S Provides Earnings Guidance for 2023

Genmab A/S Announces Submission of Japan New Drug Application for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma

Genmab A/S Showcases Data From Robust Development Program Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients Across a Broad Range of B-Cell Lymphomas at the 64th Annual ASH Meeting

Genmab A/S to Report Nine Months, 2023 Results on Nov 07, 2023

Genmab A/S Announces U.S. Food and Drug Administration Accepts for Priority Review Biologics License Application (Bla) for Epcoritamab (Duobody®-Cd3xcd20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (Lbcl)

Genmab Provides Earnings Guidance for Year 2022

Genmab A/S Submits Biologics License Application to the U.S. Food and Drug Administration

Genmab A/S Revises Earnings Guidance for the Year 2022

Genmab A/S Submits Biologics License Application to U.S. Food and Drug Administration for Epcoritamab for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma

Genmab Announces Late-Breaking Phase 2 Trial Results of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Relapsed/Refractory Large B-cell Lymphoma (LBCL) Patients Presented at European Hematology Association (EHA) Presidential Symposium

Genmab A/S and Seagen Inc. Present Data from Tisotumab Vedotin (TIVDAK) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting

Genmab A/S Revises Earnings Guidance for 2022

AbbVie and Genmab Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) from Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)

Genmab A/S Elects Elizabeth O’Farrell to the Board of Directors

Genmab A/S Announces Appointments of Birgitte Stephensen to Chief Legal Officer and Chris Cozic to Chief People Officer

Genmab A/S Provides Earnings Guidance for the Year 2022

Genmab A/S Provides Earnings Guidance for the Year 2022

Genmab A/S Announces Janssen Received Conditional European Marketing Authorization for RYBREVANT

U.S. Food and Drug Administration Grants Approval to TIVDAK

Seagen Inc. and Genmab A/S Announce FDA Accelerated Approval for TIVDAK™ (Tisotumab Vedotin-Tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer

Genmab A/S Announces the Lancet Published the Results of FIH Trial

Genmab A/S Improves Revenue Guidance for the Full Year of Fiscal 2021

Genmab A/S Announces That Janssen Has Received European Marketing Authorizations for Darzalex® (Daratumumab) Subcutaneous Formulation, Including for the Treatment of Patients with Newly Diagnosed Light-Chain (Al) Amyloidosis

Genmab Announces Janssen Received Positive CHMP Opinion Recommending DARZALEX (daratumumab) Subcutaneous (SC) Formulation for Patients with Newly Diagnosed Light-chain (AL) Amyloidosis

Genmab Announces Abstracts Evaluating Products in Pipeline, Portfolio to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) Congress

Genmab A/S Reaffirms Financial Guidance for Fiscal 2021

Genmab A/S Provides Revenue Guidance for the Full Year of Fiscal 2021

Genmab Announces Appointment of Tahamtan Ahmadi to Newly Created Position of Chief Medical Officer, Head of Experimental Medicines